[Federal Register Volume 86, Number 89 (Tuesday, May 11, 2021)]
[Notices]
[Pages 25876-25877]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-09915]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Genetic Analysis of Non-Human Animal Models to 
Understand the Genomic Architecture of Substance Use Disorders and 
Addictive Behaviors (U01 Clinical Trial Not Allowed).
    Date: June 10, 2021.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-
4471, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21).
    Date: June 11, 2021.
    Time: 10:00 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sheila Pirooznia, Ph.D., Scientific Review 
Officer, Division of Extramural Review, Scientific Review Branch, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC

[[Page 25877]]

6021, Bethesda, MD 20892, (301) 496-9350, [email protected].
    Name of Committee: National Institute on Drug Abuse Initial 
Review Group; Medication Development Research Study Section.
    Date: July 21, 2021.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Preethy Nayar, Ph.D., M.B.B.S., Scientific 
Review Officer, Scientific Review Branch, National Institute on Drug 
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 
20892, 301-443-4577, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: May 5, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-09915 Filed 5-10-21; 8:45 am]
BILLING CODE 4140-01-P